Radiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gefter, W. B.
Right arrow Articles by Miller, W. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gefter, W. B.
Right arrow Articles by Miller, W. T.

Radiology, Vol 147, 339-344, Copyright © 1983 by Radiological Society of North America

ARTICLES

Lung disease caused by amiodarone, a new antiarrythmic agent

WB Gefter, DM Epstein, GG Pietra and WT Miller

Amiodarone hydrochloride, used for prophylaxis of recurrent ventricular tachyarrhythmias that are resistant to other agents, may cause toxic pulmonary reactions associated with abnormal chest radiographs. The authors review four new cases of amiodarone-induced toxicity and eight cases reported in the literature. Peripheral areas of consolidation, predominantly in the upper lobes and resembling chronic eosinophilic pneumonia or tuberculosis, and diffuse interstitial disease were seen. Clinical symptoms included dyspnea on exertion, weakness, and occasionally pleuritic pain. Radiographic abnormalities developed after a median latency period of six months on the drug (600 to 800 mg daily). Pathologic findings suggested a possible toxic effect of the drug on phospholipid metabolism in the lung. Amiodarone toxicity may lead to significant pulmonary insufficiency. The clinical symptoms and radiographic abnormalities were completely reversible upon cessation of drug use and institution of corticosteroid treatment. Resolution generally occurs within three months.


This article has been cited by other articles:


Home page
 J CARDIOVASC PHARMACOL THERHome page
L. W. Poll, P. May, J.-A. Koch, G. Hetzel, P. Heering, and U. Modder
HRCT Findings of Amiodarone Pulmonary Toxicity: Clinical and Radiologic Regression
Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2001; 6(3): 307 - 311.
[Abstract] [PDF]

Home page
 ChestHome page
S. Y. Morelock and S. A. Sahn
Drugs and the Pleura
Chest, July 1, 1999; 116(1): 212 - 221.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
RADIOLOGY RADIOGRAPHICS RSNA JOURNALS ONLINE
Copyright © 1983 by the Radiological Society of North America.